'Betting on New Technology' | GenomeWeb

Genomic Health has made profit by selling state-of-the-art molecular diagnostics, but now it's time for some new technology to keep the company's growth momentum and revenue stream going, says Xconomy's Luke Timmerman. The company is investing in new diagnostic tests that look for patterns in more genes than today's molecular diagnostics can, Timmerman says.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.